Contributions
Abstract: EP1704
Type: Poster Sessions
Abstract Category: Therapy - Others
We aimed to study the prevalence and characteristics of headache in patients with multiple sclerosis (MS) and to clarify the relationship between headache and MS therapies.Of the total population of 754 MS patients recruited in our center, 515(68%) reported headaches. Based on headache characteristics on evaluation, 20-(27%) were diagnosed with migraine. One hundred and three patients(17%) gave a history of tension-type headache(TTH) and 198(26.3%) patients described to have medication-overuse-headache(MOH). There were 12(1.6%) patients with unclassified headache. Three- hundred and fourteen(61%) female and 201(39%) men reported headache. During our study 558 MS patients(74%) were treated with interferon beta therapy/ glatiramer acetate (DMD). 115 patients(15.3%) received fingolimod.48 MS patients (6.4%) were treated with teriflunamide, and 33 MS patients(4.4%) received natalizumab. There was no no statistical difference between DMD or NTZ use and all headache types. However, a statistically significant higher incidence of TTH was found in fingolimod-treated patients.Also, there was a higher incidence of MOH in teriflunamide-treated patients when compared to the patients who have other headaches.There was a significant association between migraine and the age of onset of MS treatments, however this significant relation was not observed in the age of onset of other agents.The mean age of onset of headaches was 27.4 years. When all headache groups were compared, the age of onset of headache was the earliest in the patients with migraine. As regards the possible relationships between duration of the history of medication use and headaches, the incidence of migraine was higher in all headache patients In all headache groups, the mean value of the headache onset after treatment started was 1.63 years. In migraine patients, the duration of medication use until the headache onset was the longest when compared to other headache groups. It is interesting to note that the consultation rates for headaches in our MS patients were not rare. Four-hundred and fifty nine patients(89%) had consulted a physician about their headaches. Approximately 154 patients(78%) with MOH were seen by physicians due to headache complaints. For migraine patients(52%), the physician consultancy tended to be higher, while this rate was less among TTH(46%) sufferers.
The results of this study indicate a possible relationship may exist between headache and MS treatments.
Disclosure: nothing to disclose
Abstract: EP1704
Type: Poster Sessions
Abstract Category: Therapy - Others
We aimed to study the prevalence and characteristics of headache in patients with multiple sclerosis (MS) and to clarify the relationship between headache and MS therapies.Of the total population of 754 MS patients recruited in our center, 515(68%) reported headaches. Based on headache characteristics on evaluation, 20-(27%) were diagnosed with migraine. One hundred and three patients(17%) gave a history of tension-type headache(TTH) and 198(26.3%) patients described to have medication-overuse-headache(MOH). There were 12(1.6%) patients with unclassified headache. Three- hundred and fourteen(61%) female and 201(39%) men reported headache. During our study 558 MS patients(74%) were treated with interferon beta therapy/ glatiramer acetate (DMD). 115 patients(15.3%) received fingolimod.48 MS patients (6.4%) were treated with teriflunamide, and 33 MS patients(4.4%) received natalizumab. There was no no statistical difference between DMD or NTZ use and all headache types. However, a statistically significant higher incidence of TTH was found in fingolimod-treated patients.Also, there was a higher incidence of MOH in teriflunamide-treated patients when compared to the patients who have other headaches.There was a significant association between migraine and the age of onset of MS treatments, however this significant relation was not observed in the age of onset of other agents.The mean age of onset of headaches was 27.4 years. When all headache groups were compared, the age of onset of headache was the earliest in the patients with migraine. As regards the possible relationships between duration of the history of medication use and headaches, the incidence of migraine was higher in all headache patients In all headache groups, the mean value of the headache onset after treatment started was 1.63 years. In migraine patients, the duration of medication use until the headache onset was the longest when compared to other headache groups. It is interesting to note that the consultation rates for headaches in our MS patients were not rare. Four-hundred and fifty nine patients(89%) had consulted a physician about their headaches. Approximately 154 patients(78%) with MOH were seen by physicians due to headache complaints. For migraine patients(52%), the physician consultancy tended to be higher, while this rate was less among TTH(46%) sufferers.
The results of this study indicate a possible relationship may exist between headache and MS treatments.
Disclosure: nothing to disclose